Jan Voss
Affiliated to Research
E-mail: jan.voss@ki.se
Visiting address: Solnavägen 9, Biomedicum, 17165 Solna
Postal address: C3 Fysiologi och farmakologi, C3 FyFa Receptorbiologi, 171 77 Stockholm
About me
- Researching protein interactions in the WNT-Frizzled pathways.
Researcher in G protein-coupled receptor and G protein pharacology, now
starting out as a postdoctoral researcher to track protein-protein
interactions along the WNT signaling pathway.
B. Sc. in Medial Biology (Duisburg-Essen University, Germany), M. Sc. in Drug
Research (University of Bonn, Germany), PhD in Drug Sciences (with Prof.
Christa Mueller, Pharmaceutical & Medicinal Chemistry, University of Bonn,
Germany).
Articles
- Journal article: ACS PHARMACOLOGY AND TRANSLATIONAL SCIENCE. 2023;6(12):1790-1800Voss JH
- Article: ISCIENCE. 2023;26(4):106492Structure-affinity and structure-residence time relationships of macrocyclic Gαq protein inhibitors.Voss JH; Crüsemann M; Bartling CRO; Kehraus S; Inoue A; König GM; Strømgaard K; Müller CE
- Article: PHARMACEUTICS. 2022;15(1):57Voss JH; Al-Hroub H; Gedschold R; Dietrich JM; Gaffal E; Toma M; Kehraus S; König GM; Brust P; Fleischmann BK; Wenzel D; Deuther-Conrad W; Müller CE
- Article: MOLECULES. 2022;27(12):3792Temirak A; Schlegel JG; Voss JH; Vaaßen VJ; Vielmuth C; Claff T; Müller CE
- Article: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION. 2022;61(22):e202115545Claff T; Klapschinski TA; Tiruttani Subhramanyam UK; Vaaßen VJ; Schlegel JG; Vielmuth C; Voß JH; Labahn J; Müller CE
- Article: ACS PHARMACOLOGY AND TRANSLATIONAL SCIENCE. 2022;5(5):373-386Voss JH; Mahardhika AB; Inoue A; Müller CE
- Article: PHARMACOLOGICAL RESEARCH. 2021;173:105880Voss JH; Nagel J; Rafehi M; Guixà-González R; Malfacini D; Patt J; Kehraus S; Inoue A; König GM; Kostenis E; Deupi X; Namasivayam V; Müller CE
- Article: JOURNAL OF NATURAL PRODUCTS. 2021;84(7):1941-1953Hanke W; Patt J; Alenfelder J; Voss JH; Zdouc MM; Kehraus S; Kim JB; Grujičić GV; Namasivayam V; Reher R; Müller CE; Kostenis E; Crüsemann M; König GM
- Article: ACS PHARMACOLOGY AND TRANSLATIONAL SCIENCE. 2021;4(2):888-897Schlegel JG; Tahoun M; Seidinger A; Voss JH; Kuschak M; Kehraus S; Schneider M; Matthey M; Fleischmann BK; König GM; Wenzel D; Müller CE
- Article: NATURE COMMUNICATIONS. 2021;12(1):144Hermes C; Richarz R; Wirtz DA; Patt J; Hanke W; Kehraus S; Voß JH; Küppers J; Ohbayashi T; Namasivayam V; Alenfelder J; Inoue A; Mergaert P; Gütschow M; Müller CE; Kostenis E; König GM; Crüsemann M
- Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2021;296:100472Patt J; Alenfelder J; Pfeil EM; Voss JH; Merten N; Eryilmaz F; Heycke N; Rick U; Inoue A; Kehraus S; Deupi X; Müller CE; König GM; Crüsemann M; Kostenis E
- Article: BRITISH JOURNAL OF PHARMACOLOGY. 2020;177(8):1898-1916Kuschak M; Namasivayam V; Rafehi M; Voss JH; Garg J; Schlegel JG; Abdelrahman A; Kehraus S; Reher R; Küppers J; Sylvester K; Hinz S; Matthey M; Wenzel D; Fleischmann BK; Pfeifer A; Inoue A; Gütschow M; König GM; Müller CE
- Article: FRONTIERS IN CHEMISTRY. 2020;8:833Kuschak M; Schlegel JG; Schneider M; Kehraus S; Voss JH; Seidinger A; Matthey M; Wenzel D; Fleischmann BK; König GM; Müller CE
All other publications
- Preprint: RESEARCH SQUARE. 2024Schulte G; Bous J; Kinsolving J; Grätz L; Scharf M; Voss J; Slecuk B; Adebali O
- Review: TRENDS IN PHARMACOLOGICAL SCIENCES. 2024;45(5):419-429Schulte G; Scharf MM; Bous J; Voss JH; Gratz L; Kozielewicz P
- Preprint: RESEARCH SQUARE. 2024Schulte G; Grätz L; Turku A; Kozielewicz P; Bowin C-F; Scharf M; Voss J; Kinsolving J; Shekhani R; Oliva-Vilarnau N; Koolmeister T; Körber M; Lauschke V; Löber S; Gmeiner P
- Review: CURRENT MEDICINAL CHEMISTRY. 2022;29(42):6359-6378Voss JH; Müller CE
Grants
- Deutsche Forschungsgemeinschaft1 January 2023 - 31 December 2025Frizzleds (FZD1-10) belong to the class F of the G protein-coupled receptor (GPCR) superfamily and play a key role in the signal transduction of secreted lipoglycoproteins of the Wingless-Int1 (WNT) family. In embryonal development, WNT signaling governs essential processes such as cellular differentiation, polarization, and migration, while in the adult, WNT signaling is involved in tissue homeostasis. Abnormal WNT and FZD signaling is related to cancer, fibrosis, arthritis, and Alzheimer’s disease. Upon WNT binding, FZDs pair with their co-receptors low-density lipoprotein receptor-related protein (LRP) 5/6 and initiate the formation of a large protein complex at the membrane, the signalosome. Signalosome formation ultimately leads to stabilization of the transcriptional cofactor β-catenin by disruption of the β-catenin-destruction complex. Due to the complexity of WNT signaling pathways, many questions remain unanswered on a molecular level, e.g. the stoichiometry of the signalosome or interaction parameters and surfaces between FZDs and their coreceptors. Furthermore, FZDs were shown to exhibit large conformational changes, typical to other GPCRs, upon ligand binding and it is currently not clear, whether and how these FZD dynamics are involved in FZD signaling. The proposed project is divided into three work packages. The first and main objective aims to form a coherent theory of FZDs in WNT signaling by integrating the concepts of signalosome formation and FZD dynamics. To this end, we will develop BRET biosensors to interrogate the protein-protein interactions between FZDs and LRPs in presence and absence of WNTs. For these experiments, we will create CRISPR-Cas9 edited cells lacking endogenous expression of respective proteins. By using additional tools, such as oncogenic FZD mutants, surrogate WNT peptides, conformational biosensors, and positive allosteric FZD modulators, we intend to characterize the FZD-LRP complex formation that initiates signalosome formation and to unravel the role of FZD dynamics in WNT signal transduction. In another work package, we intend to characterize the interaction between FZDs and other WNT-binding co-receptors, such as RO1/2, RYK, and PTK7 with similar methods. These proteins are known to play a role in WNT signaling, but currently, direct evidence for interactions between these proteins and FZDs is lacking due to unsuitable assay readouts. Lastly, we will investigate if FZDs interact with receptor-activity modifying proteins (RAMPs) and whether a possible interaction affects FZD signaling either directly or e.g. by modulating FZD trafficking in the cell.
Employments
- Postdoctoral Researcher, Department of Physiology and Pharmacology, Karolinska Institutet, 2025-2025
- Affiliated to Research, Department of Physiology and Pharmacology, Karolinska Institutet, 2025-2025